









Markets
/
Stocks
/
nasdaq-tak
/

Takeda Pharmaceutical Co Ltd

TAK

17.470USD

-0.020-0.11%

Close 02/02, 16:00（ET）Quotes delayed by 15 min

55.19BMarket Cap

76.06P/E TTM



Takeda Pharmaceutical Co Ltd

17.470

-0.020-0.11%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Takeda Pharmaceutical Co Ltd

Currency: USD Updated: 2026-02-02

Key Insights

Takeda Pharmaceutical Co Ltd's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.90.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Takeda Pharmaceutical Co Ltd's Score

Industry at a Glance

Industry Ranking

39 / 159

Overall Ranking

115 / 4529

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Takeda Pharmaceutical Co Ltd Highlights

StrengthsRisks

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 287.84%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 287.84%.

Overvalued

The company’s latest PE is 76.15, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 83.80M shares, decreasing 5.49% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 3.93M shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

18.900

Target Price

+9.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-02

The current financial score of Takeda Pharmaceutical Co Ltd is 7.61, ranking 107 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 7.78B, representing a year-over-year increase of 4.98%, while its net profit experienced a year-over-year increase of 339.11%.

Score

Industry at a Glance

Previous score

7.61

Change



Financials

6.35

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.47

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Takeda Pharmaceutical Co Ltd's Company Valuation

Currency: USD Updated: 2026-02-02

The current valuation score of Takeda Pharmaceutical Co Ltd is 5.68, ranking 144 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 76.15, which is 217.57% below the recent high of 241.82 and 86.71% above the recent low of 10.12.

Score

Industry at a Glance

Previous score

5.68

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-02

The current earnings forecast score of Takeda Pharmaceutical Co Ltd is 8.67, ranking 13 out of 159 in the Pharmaceuticals industry. The average price target is 18.00, with a high of 19.30 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

18.900

Target Price

+9.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Takeda Pharmaceutical Co Ltd

TAK

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-02

The current price momentum score of Takeda Pharmaceutical Co Ltd is 9.68, ranking 8 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 18.20 and the support level at 16.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.61

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.143

Buy

RSI(14)

75.446

Buy

STOCH(KDJ)(9,3,3)

95.230

Overbought

ATR(14)

0.338

Low Volatility

CCI(14)

152.390

Buy

Williams %R

3.116

Overbought

TRIX(12,20)

0.418

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

17.098

Buy

MA10

16.656

Buy

MA20

16.393

Buy

MA50

15.376

Buy

MA100

14.833

Buy

MA200

14.830

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-02

The current institutional shareholding score of Takeda Pharmaceutical Co Ltd is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 2.65%, representing a quarter-over-quarter increase of 6.52%. The largest institutional shareholder is Brandes Investmen, holding a total of 3.93M shares, representing 0.12% of shares outstanding, with 10.96% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Capital Research Global Investors

13.40M

+0.82%

Parametric Portfolio Associates LLC

6.05M

+1.25%

Fidelity Management & Research Company LLC

4.17M

+2.09%

UBS Financial Services, Inc.

5.86M

+47.19%

Brandes Investment Partners, L.P.

Star Investors

3.93M

+5.91%

Renaissance Technologies LLC

Star Investors

3.86M

+17.14%

Goldman Sachs Asset Management, L.P.

3.33M

+16.91%

Aperio Group, LLC

3.31M

+3.15%

TD Securities, Inc.

3.00M

Arrowstreet Capital, Limited Partnership

2.83M

+132.12%

Risk Assessment

Currency: USD Updated: 2026-02-02

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Takeda Pharmaceutical Co Ltd is 9.88, ranking 3 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.04. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.